No registrations found.
ID
Source
Brief title
Health condition
hormone naive prostate cancer metastasized to bone, hormoon naïve bot-gemetastaseerde prostaatkanker
Sponsors and support
Intervention
Outcome measures
Primary outcome
Patients with metastasized prostate cancer will undergo a [18F]FDHT PET/CT before start of ADT. A second scan will be performed three months after start of ADT.
Primary outcome is the amount of decreased uptake of 18F-FDHT per lesions before and after three months of ADT.
Secondary outcome
N/A
Background summary
N/A
Study design
Primary outcome will be measured after the second [18F]FDHT PET/CT. (3 mo’s after start of ADT).
Intervention
[18F]FDHT in PET/CT
Inclusion criteria
• metastasized prostate cancer, ≥2 lesions in bone, confirmed by
o visible lesions on bone scan, CT and/or MRI consistent with disease
o age ≥ 50 years
• no other known malignancies
• written informed consent
• no previous androgen deprivation therapy
Exclusion criteria
• active cancer besides prostate cancer
• age < 50 years
• no written informed consent
• previous androgen deprivation therapy
• imminent pathological fractures or spinal cord lesions as a result of metastases that require immediate start of androgen deprivation therapy
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL3913 |
| NTR-old | NTR4083 |
| Other | EudraCTnr : 2013-002415-10 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |